Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Christopher Loiselle,Naveen Pemmaraju,Joseph D Khoury,Hagop M Kantarjian,Meagan Rostykus,Marygrace Ward,Koji Sasaki,Courtney D Dinardo,Steven M Kornblau,Nitin Jain,Yesid Alvarado,Rita Khouri,Alessandra Ferrajoli,Jeffrey L Jorgensen,Nicholas J Short,Binru Huang,Rebecca Garris,Tapan M Kadia,Xuelin Huang,William G Wierda,Corabelle Encarnacion,Jan A Burger,Jovitta Jacob,Farhad Ravandi,Musa Yılmaz ,Guillermo Garcia‐Manero ,Marina Konopleva ,Gautam Borthakur ,Susan O’brien

doi:10.1182/blood-2019-125136

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Christopher Loiselle, Naveen Pemmaraju + Show 27 more

Open Access

https://doi.org/10.1182/blood-2019-125136

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 12

Affiliation: The University of Texas MD Anderson Cancer Center, University of California, Irvine

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Full Text